Abstracts Archive - Page 2248 of 2605 - ACR Meeting Abstracts

Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Michael E. Weinblatt¹, Clifton O. Bingham III², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴, Lenore Noonan³, Daniel Baker⁴ and Rene Westhovens⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…
Abstract Number: 2769 • 2013 ACR/ARHP Annual Meeting
Clinical Remission After 52 Weeks Of Treatment Is a Predictor Of Adalimumab-Free Disease Control In Patients With Early Rheumatoid Arthritis: Hopeful 2 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Tadamichi Kubo⁶, Aki Kuroki⁷ and Tsutomu Takeuchi⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical Affairs, AbbVie GK, Tokyo, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although it is possible to achieve remission or low disease activity (LDA) with the combination of methotrexate (MTX) and biologics for many patients with…
Abstract Number: 2770 • 2013 ACR/ARHP Annual Meeting
Complex Functional Effects Within The HLA Contribute To Sjögren’s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding
Christopher J. Lessard^1,2, He Li¹, Indra Adrianto¹, John A. Ice¹, Mikhail G. Dozmorov³, Roland Jonsson⁴, Maureen Rischmueller⁵, Gunnel Nordmark⁶, Xavier Mariette⁷, Corinne Miceli-Richard⁸, Marie Wahren-Herlenius⁹, Torsten Witte¹⁰, Michael T. Brennan¹¹, Roald Omdal¹², Lars Rönnblom¹³, Patrick M. Gaffney¹, Wan-Fai Ng¹⁴, Nelson L. Rhodus¹⁵, Barbara M. Segal¹⁶, Jonathan D. Wren¹, R. Hal Scofield^1,17,18, Juan-Manuel Anaya¹⁹, John B. Harley^20,21, Courtney G. Montgomery¹ and Kathy L. Sivils^1,2, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁷Paris-Sud University, Paris, France, ⁸Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁹Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹¹Nidcr NIH, Carolinas Medical Center, Charlotte, NC, ¹²Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹³Department of Medical Science, Uppsala University, Uppsala, Sweden, ¹⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁸US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁹School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ²⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²¹US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common, heterogeneous exocrinopathy. Etiology involves complex environmental, genetic and genomic influences driving innate and adaptive autoimmune responses. This…
Abstract Number: 2771 • 2013 ACR/ARHP Annual Meeting
The NKp30/B7H6 Axis Contributes To Pathogenesis In Primary Sjögren’s Syndrome
Gaetane Nocturne¹, Sylvie Rusakiewicz², Damien Sene³, Gunnel Nordmark⁴, Maija-Leena Eloranta⁵, Per Eriksson⁶, Elke Theander⁷, Helena Forsblad-d'Elia⁸, Roald Omdal⁹, Marie Wahren-Herlenius¹⁰, Roland Jonsson¹¹, Lars Rönnblom⁵, Joanne Nititham¹², Kimberly E. Taylor¹³, Christopher J. Lessard¹⁴, Kathy L. Moser¹⁵, Jacques-Eric Gottenberg¹⁶, Lindsey A. Criswell¹², Corinne Miceli-Richard¹⁷, Laurence Zitvogel¹⁸ and Xavier Mariette¹⁹, ¹INSERM U1012, Université Paris Sud, Le Kremlin Bicêtre, France, ²IGR INSERM U1015, Villejuif, France, ³Internal Medecine, Pitie-Salpetriere Hospital, Paris, France, ⁴Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁵Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁶Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁸Rheumatology, University of Gothenburg, Gothenburg, Sweden, ⁹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹⁰Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Strasbourg University Hospital, Strasbourg, France, ¹⁷Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ¹⁸IGR INSERM U1015, Villejuif, France, ¹⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: NK cells are an important subset of cells involved in innate immunity. Their possible role has never been studies in pSS pathogeny. We aimed…
Abstract Number: 2772 • 2013 ACR/ARHP Annual Meeting
Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching
He Li^1,2, John A. Ice³, Jennifer A. Kelly³, Indra Adrianto¹, Stuart B. Glenn³, Kimberly S. Hefner⁴, Evan G. Vista⁵, Donald U. Stone⁶, Raj Gopalakrishnan⁷, Glen D. Houston⁸, David M. Lewis⁹, Michael Rohrer⁷, Pamela Hughes⁷, John B. Harley^10,11, Courtney G. Montgomery³, James Chodosh¹², James A. Lessard¹³, Juan-Manuel Anaya¹⁴, Barbara M. Segal¹⁵, Nelson L. Rhodus¹⁶, Lida Radfar², R. Hal Scofield¹⁷, Christopher J. Lessard^3,18 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁶Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁸Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹¹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹³Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁴Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁵Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of the European population.…
Abstract Number: 2773 • 2013 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Patterns In naïve CD4+ T Cells From Patients With Primary Sjögren’s Syndrome
Nezam I. Altorok¹, Patrick S. Coit², Travis Hughes², Kristi A. Koelsch³, R. Hal Scofield⁴, Kathy L. Sivils⁵, A. Darise Farris⁶ and Amr H. Sawalha², ¹Internal Medicine and Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK
Background/Purpose: Primary Sjögren’s syndrome (PSS) is a systemic autoimmune disease characterized by inflammation of the lacrimal and salivary glands and dryness of the eyes and mouth.…
Abstract Number: 2774 • 2013 ACR/ARHP Annual Meeting
Distinct Role Of Plasmacytoid Dendritic Cells and Mast Cells In The Pathogenesis Of Sjӧgren’s Syndrome
Jidong Zhao¹, Kunihiro Yamaoka¹, Satoshi Kubo¹, Shingo Nakayamada² and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Sjögren’s Syndrome (SS) is characterized by the destruction of the lacrimal and salivary grands due to autoreactive lymphocyte infiltration in the early phase and…
Abstract Number: 2775 • 2013 ACR/ARHP Annual Meeting
Adenosine A2b Receptor Agonist Bay60-6583 Restores Salivary Gland Function In a Mouse Model For Sjögren’s Syndrome
Barbara Szczerba¹, Paulina Rybakowska¹, Paromita Dey¹, Harini Bagavant¹ and Umesh Deshmukh², ¹Department of Medicine, University of Virginia, Charlottesville, VA, ²Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disorder mainly affecting the exocrine glands. However, it is now clear that both immune and non-immune…
Abstract Number: 2746 • 2013 ACR/ARHP Annual Meeting
A Novel Autoinflammatory Disorder Characterized By Ectodermal Dysplasia, Metaphyseal Chondrodysplasia, Growth Failure and Hyper-IgD In a Single Family
Edward J. Oberle^1,2 and James W. Verbsky^1,3, ¹Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ²Rheumatology, Children's Hospital of Wisconsin, Milwaukee, WI, ³Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Autoinflammatory disorders are characterized by chronic inflammation, and a variety of systemic complaints. Defects in the NF-kb essential modifier, or NEMO, are associated…
Abstract Number: 2747 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment In Schnitzler’s Syndrome: A Multi-Center Randomized Placebo-Controlled 4-Month Study
Karoline Krause, Karsten Weller, Martin Metz and Marcus Maurer, Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany
Background/Purpose: Schnitzler’s syndrome (SchS) is an adult-onset autoinflammatory disease characterized by urticarial exanthema and monoclonal gammopathy in combination with episodes of fever, arthralgia, fatigue, and…
Abstract Number: 2736 • 2013 ACR/ARHP Annual Meeting
High Density Microarray Analysis Identifies Novel Differentially Expressed Long Noncoding RNAs In Rheumatoid Arthritis Synovial Fibroblasts
Mojca Frank Bertoncelj¹, Michelle Trenkmann¹, Christoph Kolling², Beat A. Michel³, Renate E. Gay⁴ and Steffen Gay¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Schultess Clinic, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) have emerged as key regulators of gene expression. Recently, several new susceptibility loci were identified for rheumatoid arthritis (RA), mapping…
Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 2738 • 2013 ACR/ARHP Annual Meeting
Microrna-Mediated Regulation Explains Allelic Risk Of TLR7 Variant Predisposing To Systemic Lupus Erythematosis
Yun Deng¹, Jian Zhao¹, Jennifer M. Grossman² and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: We identified a genome-wide significant association of the TLR7 variant (rs3853839) with SLE susceptibility in multiple ancestries (Pmeta =2.0×10-19, OR =1.25), and the risk…
Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting
Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Maureen D. Mayes for the US Scleroderma GWAS Group¹, Lara Bossini-Castillo for the Spanish Scleroderma Group², Olga Gorlova³, Jose Ezequiel Martin⁴, Xiaodong Zhou¹, Wei Chen⁵, Shervin Assassi¹, Jun Ying⁵, John D. Reveille¹, Peter K. Gregersen⁶, Annette T. Lee⁷, Maria Teruel⁸, Francisco David Carmona⁴, Bobby P.C. Koeleman⁹, Matthew A. Brown and the Immunochip Consortium¹⁰, Christopher P. Denton¹¹, Murray Baron for the Canadian Scleroderma Research Group¹², Jasper Broen¹³, T.R.D.J. Radstake¹³ and Javier Martin⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ⁵Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ¹³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].